8-K: Veradigm Files 2023 & 2024 10-K, Eyes 2025/2026 Filings

Veradigm Inc. announced the filing of its Annual Reports on Form 10-K for fiscal years 2023 and 2024, marking a significant step towards regaining current SEC filing status.

Summary

• Veradigm Inc. has filed its Annual Reports on Form 10-K for the fiscal years ended December 31, 2023, and December 31, 2024.
• The company is now focusing on completing its filings for fiscal years 2025 and 2026, with the 2025 Form 10-K expected before the end of 2026.
• Historical revenue for 2024 was $594 million, down from $626 million in 2023 (which included $19 million in non-recurring revenue).
• The company reported a Net Loss of $292 million in 2024, compared to a Net Income of $49 million in 2023.
• Adjusted EBITDA was $94 million in 2024, down from $132 million in 2023.
• Preliminary estimated unaudited financial information for fiscal year 2025 projects revenue between $584 million and $589 million.
• Estimated Net Cash as of December 31, 2025, is $45 million, with $120 million in cash and $75 million in debt.
• The company aims to relist its common stock on a national exchange.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant financial deterioration in 2024, despite the positive step of filing historical reports.

Positives

• Successful filing of the 2023 and 2024 Form 10-K, a major milestone in becoming current with SEC filings.
• Reaffirmation of preliminary 2025 financial estimates, indicating management confidence in future performance.
• Focus on strategic reset and recovery of leadership with independent practices.
• Anticipated benefit to 2026 full-year revenue from a more focused product and platform strategy.
• Expected positive impact on profitability in 2026 from AI investments and cost actions.

Negatives

• Revenue decreased from $626 million in 2023 to $594 million in 2024.
• Net Loss of $292 million in 2024, a significant decline from a Net Income of $49 million in 2023.
• Adjusted EBITDA decreased from $132 million in 2023 to $94 million in 2024.
• The 2024 net loss was significantly impacted by goodwill and other asset impairment, and transaction costs.
• The company's common stock is currently trading on OTC Expert Market (OTCMKTS: MDRX).

Risks

• Risk of further material delay in financial reporting or inability to hold an annual meeting.
• Potential for additional errors or material weaknesses identified during the audit of 2025 financial statements.
• Possibility that control deficiencies will result in additional material weaknesses in internal control over financial reporting.
• Ongoing litigation, including a putative securities class action lawsuit and a stockholder derivative action.
• Risks related to the common stock not trading on a national securities exchange and deregistration from Section 12(b).
• Changes in the financial condition of the markets served by the company.
• Risks related to recent executive leadership transitions.

Future Outlook

The company expects 2026 full-year revenue to benefit from a more focused product and platform strategy, with profitability positively impacted by AI-specific investments and cost actions taken since fall 2025. The 2025 Form 10-K is expected to be filed before the end of 2026.

Management Comments

• "Today marks a major milestone in that important effort... We have reset our strategic focus and, with Christian Greyenbuhl in place as our new Chief Financial Officer, we have the senior team required to recover our leadership with independent practices and reignite profitable growth."
• "We are encouraged by early signs of progress from our first-quarter 2026 performance. We expect 2026 full-year revenue will benefit from a more focused product and platform strategy. Profitability will be positively impacted by our AI-specific investments and cost actions taken since fall 2025."

Industry Context

StockSavvy.ai notes that Veradigm's focus on filing historical SEC reports and its emphasis on AI investments align with broader industry trends in healthcare technology, where efficiency gains and data-driven insights are increasingly critical for providers.

Comparison to Industry Standards

• No direct comparisons to specific industry benchmarks or competitors were provided in the filing.
• The company's revenue decline in 2024 and significant net loss are concerning metrics compared to industry averages for stable, growing software and services companies.

Management Changes

Legal Proceedings

• Putative securities class action lawsuit filed against the Company.
• Putative stockholder derivative action filed against the Company.
• Commercial litigation relating to the Company's representations regarding its financial statements.
• Potential for other future litigation or investigations related to internal control failures.

Stakeholder Impact

• Shareholders: Potential impact from stock not trading on a national exchange and the ongoing need to regain current filing status. The financial performance directly affects shareholder value.
• Employees: Management changes and financial performance may impact morale and compensation. Stock-based compensation is a key incentive.
• Creditors: The company has $75 million in debt as of December 31, 2025, with a term loan facility maturing in 2030. Financial performance impacts the company's ability to service this debt.

Next Steps

• Complete the filing of the Form 10-K for the fiscal year ended December 31, 2025, expected before year-end 2026.
• Host an investor conference call and webcast on May 27, 2026, to discuss the company's update.
• Focus on recovering leadership with independent practices and reigniting profitable growth.
• Work towards relisting the company's common stock on a national exchange.

Key Dates

Recommendation

While the filing of historical reports is a positive step towards compliance, the significant financial deterioration in 2024 and ongoing legal risks warrant a cautious 'hold' recommendation. Investors should await further clarity on the 2025/2026 filings and the company's ability to execute its turnaround strategy.

Keywords

Veradigm, 8-K, SEC Filing, 10-K, Financial Report, Annual Report, Clinical Solutions, Revenue Cycle